Cargando…
Unmasking Adenosine: The Purinergic Signalling Molecule Critical to Arrhythmia Pathophysiology and Management
Adenosine was identified in 1929 and immediately recognised as having a potential role in therapy for arrhythmia because of its negative chronotropic and dromotropic effects. Adenosine entered mainstream use in the 1980s as a highly effective agent for the termination of supraventricular tachycardia...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358948/ https://www.ncbi.nlm.nih.gov/pubmed/32685154 http://dx.doi.org/10.15420/aer.2019.05 |
_version_ | 1783558946659762176 |
---|---|
author | Matthews, Gareth DK Grace, Andrew A |
author_facet | Matthews, Gareth DK Grace, Andrew A |
author_sort | Matthews, Gareth DK |
collection | PubMed |
description | Adenosine was identified in 1929 and immediately recognised as having a potential role in therapy for arrhythmia because of its negative chronotropic and dromotropic effects. Adenosine entered mainstream use in the 1980s as a highly effective agent for the termination of supraventricular tachycardia (SVT) involving the atrioventricular node, as well as for its ability to unmask the underlying rhythm in other SVTs. Adenosine has subsequently been found to have applications in interventional electrophysiology. While considered a safe agent because of its short half-life, adenosine may provoke arrhythmias in the form of AF, bradyarrhythmia and ventricular tachyarrhythmia. Adenosine is also associated with bronchospasm, although this may reflect irritant-induced dyspnoea rather than true obstruction. Adenosine is linked to numerous pathologies relevant to arrhythmia predisposition, including heart failure, obesity, ischaemia and the ageing process itself. This article examines 90 years of experience with adenosine in the light of new European Society of Cardiology guidelines for the management of SVT. |
format | Online Article Text |
id | pubmed-7358948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Radcliffe Cardiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73589482020-07-17 Unmasking Adenosine: The Purinergic Signalling Molecule Critical to Arrhythmia Pathophysiology and Management Matthews, Gareth DK Grace, Andrew A Arrhythm Electrophysiol Rev Drugs and Devices Adenosine was identified in 1929 and immediately recognised as having a potential role in therapy for arrhythmia because of its negative chronotropic and dromotropic effects. Adenosine entered mainstream use in the 1980s as a highly effective agent for the termination of supraventricular tachycardia (SVT) involving the atrioventricular node, as well as for its ability to unmask the underlying rhythm in other SVTs. Adenosine has subsequently been found to have applications in interventional electrophysiology. While considered a safe agent because of its short half-life, adenosine may provoke arrhythmias in the form of AF, bradyarrhythmia and ventricular tachyarrhythmia. Adenosine is also associated with bronchospasm, although this may reflect irritant-induced dyspnoea rather than true obstruction. Adenosine is linked to numerous pathologies relevant to arrhythmia predisposition, including heart failure, obesity, ischaemia and the ageing process itself. This article examines 90 years of experience with adenosine in the light of new European Society of Cardiology guidelines for the management of SVT. Radcliffe Cardiology 2019-12 /pmc/articles/PMC7358948/ /pubmed/32685154 http://dx.doi.org/10.15420/aer.2019.05 Text en Copyright © 2019, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/legalcode This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly. |
spellingShingle | Drugs and Devices Matthews, Gareth DK Grace, Andrew A Unmasking Adenosine: The Purinergic Signalling Molecule Critical to Arrhythmia Pathophysiology and Management |
title | Unmasking Adenosine: The Purinergic Signalling Molecule Critical to Arrhythmia Pathophysiology and Management |
title_full | Unmasking Adenosine: The Purinergic Signalling Molecule Critical to Arrhythmia Pathophysiology and Management |
title_fullStr | Unmasking Adenosine: The Purinergic Signalling Molecule Critical to Arrhythmia Pathophysiology and Management |
title_full_unstemmed | Unmasking Adenosine: The Purinergic Signalling Molecule Critical to Arrhythmia Pathophysiology and Management |
title_short | Unmasking Adenosine: The Purinergic Signalling Molecule Critical to Arrhythmia Pathophysiology and Management |
title_sort | unmasking adenosine: the purinergic signalling molecule critical to arrhythmia pathophysiology and management |
topic | Drugs and Devices |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358948/ https://www.ncbi.nlm.nih.gov/pubmed/32685154 http://dx.doi.org/10.15420/aer.2019.05 |
work_keys_str_mv | AT matthewsgarethdk unmaskingadenosinethepurinergicsignallingmoleculecriticaltoarrhythmiapathophysiologyandmanagement AT graceandrewa unmaskingadenosinethepurinergicsignallingmoleculecriticaltoarrhythmiapathophysiologyandmanagement |